5′,-substituted adenosynes preparation thereof and use as inhibitors of S-adenosylmethionine decarboxylase
The crystal structure of the complex of S-adenosylmethionine methyl ester with hΛdoMetDC F223A, a mutant where the stacking of the aromatic rings of F7, adenine and F223 would be eliminated. The structure of this mutant with the ester shows that the ligand still maintains a syn conformation aided by pi-pi interactions to F7, hydrogen bonds to the backbone of Glu67, and electrostatic interactions. Several series of AdoMet substrate analogues with a variety of substituents at the 8 position of adenine were synthesized and analyzed for their ability to inhibit hAdoMetDC. To understand these results, virtual modeling of the enzyme inhibitor complexes and the crystal structures of human AdoMetDC with 5′-deoxy-5′-[N-methyl-N-[2-(aminooxy)ethyl]amino-8-methyl]adenosine (MAOEMA) and 5′-deoxy-5′-[N-methyl-N-[4-(aminooxy)butyl]amino-8-ethyl]adenosine (MAOBEA) at the active site have been determined experimentally.
1. A compound represented by the formula;
pharmaceutically acceptable salt thereof; and solvate thereof; wherein each of R 1 and R 2 individually is selected from the group consisting of H and alkyl; R 4 is selected from the group consisting of NR 7 R 8 ; each of R 7 and R 8 individually is selected from the group consisting of alkyl, (CH 2 ) n NR 1 R 2 , (CH 2 ) n CONR 1 R 2 and (CH 2 ) n C═ONR 1 R 2 ; wherein n is a whole number integer from 1 to 8; each of R 5 and R 6 individually is selected from the group consisting of H and acyl; and wherein R 3 is alkyl.
2. The compound according to claim 1 wherein each R 1 and R 2 is H.
3. The compound according to claim 1 wherein each R 5 and R 6 is H.
4. The compound according to claim 1 wherein R 3 is methyl.
5. A pharmaceutical composition comprising an effective amount of a compound or pharmaceutically acceptable salt thereof, or solvate thereof, according to claim 1 , and a pharmaceutically acceptable carrier.
6. A method of treating a host suffering from a parasitic infection or an infection from caused by Pneumocystis cainii which comprises administering to said host an effective amount of a compound; pharmaceutically acceptable salt thereof or solvate thereof, according to claim 1 .
7. The method according to claim 6 wherein said infection is a protozoal infection.
8. The method according to claim 7 wherein said infection is trypanosomiasis or malaria.
9. A pharmaceutical composition comprising an effective amount of a compound or pharmaceutically acceptable salt thereof, or a solvate thereof, according to claim 2 , and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising an effective amount of a compound or pharmaceutically acceptable salt thereof, or a solvate thereof, according to claim 3 , and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising an effective amount of a compound or pharmaceutically acceptable salt thereof, or a solvate thereof, according to claim 1 , and a pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising an effective amount of a compound or pharmaceutically acceptable salt thereof, or a solvate thereof, according to claim 4 , and a pharmaceutically acceptable carrier.
13. A method for inhibiting S-adenosylmethionine decarboxylase in a host in need thereof which comprises administering to said host an effective amount of a compound; pharmaceutically acceptable salt thereof or solvate thereof, according to claim 2 .
14. A method for inhibiting S-adenosylmethionine decarboxylase in a host in need thereof which comprises administering to said host an effective amount of a compound; pharmaceutically acceptable salt thereof or solvate thereof, according to claim 3 .
15. A method for inhibiting S-adenosylmethionine decarboxylase in a host in need thereof which comprises administering to said host an effective amount of a compound; pharmaceutically acceptable salt thereof or solvate thereof, according to claim 1 .
16. A method for inhibiting S-adenosylmethionine decarboxylase in a host in need thereof which comprises administering to said host an effective amount of a compound; pharmaceutically acceptable salt thereof or solvate thereof, according to claim 4 .
17. A method of treating a host suffering from a parasitic infection or an infection from caused by Pneumocystis cainii which comprises administering to said host an effective amount of a compound; pharmaceutically acceptable salt thereof or solvate thereof, according to claim 2 .
18. A method of treating a host suffering from a parasitic infection or an infection from caused by Pneumocystis cainii which comprises administering to said host an effective amount of a compound; pharmaceutically acceptable salt thereof or solvate thereof, according to claim 3 .
19. A method of treating a host suffering from a parasitic infection or an infection from caused by Pneumocystis cainii which comprises administering to said host an effective amount of a compound; pharmaceutically acceptable salt thereof or solvate thereof, according to claim 4 .